Virbac announces the resignation of Sébastien Huron from his position as Executive Managing Director: he will be leaving the animal health group's general management by September 30, to take a break from his professional life.
As a result, current Deputy Managing Director and CFO Habib Ramdani has been appointed interim Executive Managing Director, while the Nominations and Remuneration Committee recruits the next Managing Director.
After working at Ipsen, Habib Ramdani joined Virbac in 2016 as CFO and member of the Management Board, before being appointed Deputy CEO and member of the Group Management Committee in December 2020.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows:
- pet medications (61.6%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications (38.4%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: Europe (40.8%), Latin America (15.9%), North America (13%), India/Africa/Middle East (12.5%), East Asia (10.1%) and Pacific (7.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
